Xometry has received coverage from ten analyst firms, yielding an average recommendation of Hold. One analyst has issued a Sell rating, four maintain a Hold stance and five recommend Buy. The consensus 12-month price objective across these reports stands at $57.89, reflecting a balanced view of the company’s near-term growth prospects.

On November 5, multiple brokerages raised their targets for Xometry. Citizens Jmp increased its objective from $65 to $75 and upgraded the rating to Market Outperform. Cantor Fitzgerald lifted its target from $41 to $60, maintaining a Neutral rating. JMP Securities set a $75 target, Wedbush raised its view from $48 to $70 with an Outperform designation, and JPMorgan Chase & Co. moved its target from $55 to $70, assigning an Overweight rating.

Chief Financial Officer James Miln sold 599 shares for proceeds of approximately $37,204, reducing his stake by 0.42% to 141,796 shares. Director Subir Dutt disposed of 2,075 shares at an average price of $60, netting $124,500 and trimming his holdings to 71,348 shares (a 2.83% decrease). Over the past 90 days insiders have sold 12,005 shares totaling $631,147, and corporate insiders now hold 9.66% of outstanding stock.

In its latest quarter, Xometry reported revenue of $180.72 million, up 27.5% year-over-year and exceeding the consensus of $168.25 million. Earnings per share came in at $0.11, matching analyst expectations. The company’s gross margin expanded modestly, though its net margin remained negative at 9.8%. Xometry ended the period with a current ratio of 3.62 and a debt-to-equity ratio of 1.20, reflecting a strong liquidity position amid ongoing investment in platform and supplier network expansion.